Latest Views & News

Advanced Oncotherapy – Ignore Director Buying As Placing Approaches

By Nigel Somerville, the Deputy Sheriff of AIM | Saturday 5 March 2022

Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.

AIM-listed and surely sort of cash Advanced Oncotherapy (AVO) announced yesterday morning that Prof Stephen Myers, executive director and the chairman of ADAM – Advanced’s development team in Geneva – had bought a total of 140,000 shares. At 27.64p (on average) that is £38,700 worth of stock. It sounds quite impressive, but this is certainly not a situation where it is advisable to follow director buying. In fact, I take the opposite view: the shares are a sell.

You must be a registered member to read this story
ShareProphets is reader-supported journalism

Join us for free and gain access to three articles per month

Or become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.

Filed under:

Subscribe to our newsletter

Daily digest of our latest stories.

Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was



The ShareProphets Sunday Pub Quiz #160



Gyrations at Victoria Carpets



GOTCHA: admits it is fucked



Stuff happens but we are not stuffed



The ShareProphets Sunday Pub Quiz #159



Challenges continue at Ocado



Iconic Labs – back from the dead?



Pure Gold – Pure Ramping!

Sunday »


The ShareProphets Sunday Pub Quiz #158



Buy Orcadian Energy